Education
About Us
Working with TipRanks
Follow Us
Eton Pharmaceuticals Inc (ETON)
NASDAQ:ETON
ETON Stock Chart & Stats
$17.45
-$0.03(-0.25%)
At close: 4:00 PM EST
$17.45
-$0.03(-0.25%)
Day’s Range― - ―
52-Week Range$11.09 - $23.00
Previous CloseN/A
Volume127.06K
Average Volume (3M)263.58K
Market Cap
$467.97M
Enterprise Value$435.98M
Total Cash (Recent Filing)$37.12M
Total Debt (Recent Filing)$3.26M
Price to Earnings (P/E)―
Beta1.09
Next Earnings
Mar 19, 2026EPS Estimate
0.13Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.04
Shares Outstanding26,817,535
10 Day Avg. Volume363,229
30 Day Avg. Volume263,583
Financial Highlights & Ratios
PEG Ratio-0.29
Price to Book (P/B)14.12
Price to Sales (P/S)8.84
P/FCF Ratio365.77
Enterprise Value/Market Cap0.93
Enterprise Value/Revenue6.20
Enterprise Value/Gross Profit12.07
Enterprise Value/Ebitda329.54
Forecast
1Y Price Target
$31.00Price Target Upside77.65% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)1.01
Revenue Forecast (FY)$102.93M
Bulls Say, Bears Say
Bulls Say
Revenue MomentumSustained top-line acceleration to TTM $70.3M and 19 consecutive quarters of sequential growth indicate durable commercial traction. A multi-product mix (ALKINDI, Carglumic Acid, INCRELEX, GALZIN) shows scalable sales execution and repeatable demand across niche pediatric and rare-disease channels.
Cash GenerationRobust operating and free cash flow in the TTM period reflects a structural shift to positive cash-generation after prior years of outflows. This enhances funding flexibility for launches, BD, and label studies without sizable external financing, strengthening long-term operational independence.
De-risked Balance SheetSignificantly lower leverage vs. prior periods materially reduces financial risk and interest burden. A healthier capital structure supports continued M&A and licensing activity, and gives management runway to commercialize ultra-rare assets while limiting refinancing pressure.
Bears Say
Persistent LossesDespite revenue and cash-flow gains, the company remains unprofitable on a net income basis in the TTM. Continued losses constrain return metrics and could limit ability to sustainably invest in marketing or R&D without dilutive financing if cash generation weakens.
Regulatory Label RestrictionAn FDA age-based restriction on KHINDIVI structurally reduces addressable market in the largest unmet pediatric cohort. Expanding the label will require additional safety data or reformulation, delaying revenue expansion and adding clinical and commercial execution risk over multiple quarters.
Narrow Patient Dynamics (INCRELEX)Flat active patient counts and aging-out dynamics create a structural ceiling on organic growth for INCRELEX absent label expansion or new indications. Reliance on small, churn-prone patient populations increases revenue volatility and raises the bar for successful BD or label-harmonization efforts.
Eton Pharmaceuticals News
ETON FAQ
What was Eton Pharmaceuticals Inc’s price range in the past 12 months?
Eton Pharmaceuticals Inc lowest stock price was $11.09 and its highest was $23.00 in the past 12 months.
What is Eton Pharmaceuticals Inc’s market cap?
Eton Pharmaceuticals Inc’s market cap is $467.97M.
When is Eton Pharmaceuticals Inc’s upcoming earnings report date?
Eton Pharmaceuticals Inc’s upcoming earnings report date is Mar 19, 2026 which is in 15 days.
How were Eton Pharmaceuticals Inc’s earnings last quarter?
Eton Pharmaceuticals Inc released its earnings results on Nov 06, 2025. The company reported $0.04 earnings per share for the quarter, missing the consensus estimate of $0.09 by -$0.05.
Is Eton Pharmaceuticals Inc overvalued?
According to Wall Street analysts Eton Pharmaceuticals Inc’s price is currently Undervalued.
Does Eton Pharmaceuticals Inc pay dividends?
Eton Pharmaceuticals Inc does not currently pay dividends.
What is Eton Pharmaceuticals Inc’s EPS estimate?
Eton Pharmaceuticals Inc’s EPS estimate is 0.13.
How many shares outstanding does Eton Pharmaceuticals Inc have?
Eton Pharmaceuticals Inc has 26,817,535 shares outstanding.
What happened to Eton Pharmaceuticals Inc’s price movement after its last earnings report?
Eton Pharmaceuticals Inc reported an EPS of $0.04 in its last earnings report, missing expectations of $0.09. Following the earnings report the stock price went down -11.703%.
Which hedge fund is a major shareholder of Eton Pharmaceuticals Inc?
Currently, no hedge funds are holding shares in ETON
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Eton Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$31.00 (77.65% Upside)
$31.00 (77.65% Upside)
Blogger Sentiment
Bullish
ETON Sentiment 75%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 86.1K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $132.6K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 5.5%
Last 30 Days ▲ 14.5%
Last 30 Days ▲ 14.5%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
16.10%
12-Months-Change
Fundamentals
Return on Equity
-34.17%
Trailing 12-Months
Asset Growth
191.59%
Trailing 12-Months
Company Description
Eton Pharmaceuticals Inc
Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing pharmaceutical products for rare diseases. The company offers Biorphen, a phenylephrine injection for the treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; and Rezipres, a ready-to-use formulation of a molecule that is indicated for the treatment of clinically important hypotension occurring in the setting of anesthesia. It also offers Alkindi Sprinkle, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; EPRONTIA, a liquid formulation of topiramate; and Alaway Preservative Free, a preservative-free ophthalmic product to treat allergic conjunctivitis. In addition, the company develops Zonisamide Oral Suspension for the treatment of partial on-set seizures; Lamotrigine for Oral Suspension for the treatment of partial on-set seizures; cysteine injection; dehydrated alcohol injection; and Zeneo hydrocortisone autoinjector. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.
ETON Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
Eton Pharmaceuticals experienced substantial revenue growth and strong performance from key products, leading to positive cash flow generation and profitability. However, the company faced challenges with net income, patient count for INCRELEX, and FDA restrictions on KHINDIVI. Despite these challenges, the overall outlook remains positive with strategic initiatives underway.View all ETON earnings summariesETON Stock 12 Month Forecast
Average Price Target
$31.00
▲(77.65% Upside)
Technical Analysis
Ownership Overview
25.56% Insiders
8.27% Mutual Funds
31.20% Other Institutional Investors
26.59% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---